DUBLIN, IRELAND – December 5th, 2014 – Actavis plc (NYSE: ACT) today announced that its subsidiary Forest Laboratories, LLC will present data on its mental health portfolio for currently marketed products levomilnacipran and vilazodone at the 53rd Annual Meeting of the American College of Neuropsychopharmacology (ACNP) December 7-10, 2014 in Phoenix, Arizona.
Data accepted include trial results for levomilnacipran, a serotonin and norepinephrine reuptake inhibitor (SNRI) approved for the treatment of major depressive disorder (MDD) in adults. Results will be presented from post-hoc pooled analyses of five Phase II/III trials looking at the effects of levomilnacipran on MDD symptoms, effects on cognition and improvements in functional impairment.
Actavis also announced that two poster presentations have been accepted at ACNP: results on vilazodone, a selective serotonin reuptake inhibitor (SSRI) and 5-HT1A receptor partial agonist approved for the treatment of MDD in adults. These include safety and efficacy Phase III findings of vilazodone for the treatment of generalized anxiety disorder, and data on the sexual side effect profile of male rats switched from paroxetine to vilazodone.
The levomilnacipran results will be announced in three poster presentations: December 9th 5:30-7:30:
• Noradrenergic-Related Depression Symptoms in Patients with Major Depressive Disorder: Post Hoc Analysis of 5 Clinical Trials of Levomilnacipran Extended-Release (poster T107)
• Effects of Levomilnacipran ER on Cognition and Functioning in Patients with Major Depressive Disorder: Post Hoc Analysis of a Phase 3 Trial (poster T106)
• Effects of Levomilnacipran ER on Motivation/Energy and Functional Impairment in Adults with Major Depressive Disorder: Post Hoc Analysis of a Phase 3 Trial (poster T80)
The vilazodone results will be announced in two poster presentations: December 8th, 5:30-7:30:
• Switching From Paroxetine to Vilazodone Significantly Reduces Sexual Side Effects in Male Rats (poster M27)
December 9th, 5:30-7:30:
• Efficacy and Safety of Vilazodone in Generalized Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Trial (poster T82)
About Actavis
Actavis plc (NYSE:ACT), headquartered in Dublin, Ireland, is a unique specialty pharmaceutical company focused on developing, manufacturing and commercializing high quality affordable generic and innovative branded pharmaceutical products for patients around the world.
Actavis markets a broad portfolio of branded and generic pharmaceuticals and develops innovative medicines for patients suffering from diseases principally in the central nervous system, gastroenterology, women’s health, urology, cardiovascular, respiratory and anti-infective therapeutic categories. The Company is an industry leader in product research and development, with one of the broadest brand development pipelines in the pharmaceutical industry, and a leading position in the submission of generic product applications. Actavis has commercial operations in more than 60 countries and operates more than 30 manufacturing and distribution facilities around the world.
For more information, visit Actavis’ website at www.actavis.com.
Help employers find you! Check out all the jobs and post your resume.
